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The p16/MTS1 gene is altered by deletion, mutation,
or hypermethylation in a wide variety of human can-
cers. As a result of deficient p16 protein, these can-
cers lack a critical mechanism for halting Gi/S celi
cycle progression. In the current study, 59 cases of
nasopharyngeal carcinoma were evaluated for ex-
pression of the p16 tumor suppressor protein by im-
munohistochemical analysis of paraffin-embedded
tissue. There was no detectable p16 in 38/59 cases
(64%), which implies a very high rate of p16 inacti-
vation in this type of cancer. On the other hand, the
retinoblastoma gene product, which also regulates
the GI to S phase transition of the cell cycle, was
consistently expressed in nasopharyngeal carcino-
mas by immunohistochemical analysis. These results
implicate p16 inactivation but not Rb alteration in
the stepwise progression of nasopharyngeal carcin-
ogenesis. (Am J Patbol 1998, 152:865-869)
Nasopharyngeal carcinoma (NPC) is unique among can-
cers of the head and neck in that it affects younger
patients, is only weakly associated with alcohol and to-
bacco use, frequently has an undifferentiated histological
appearance, and is associated with Epstein-Barr virus
(EBV) infection. Nevertheless, like most carcinomas, its
pathogenesis probably depends on the multistep accu-
mulation of genetic defects.
Recurrent cytogenetic abnormalities of chromosome
9p21 in NPC suggest the possibility of a tumor suppres-
sor gene in that region that is operative in carcinogene-
sis.1 At 9p21 lies the p16 gene (MTS1; CDKN2) encoding
a 16-kd protein that inhibits cdk4 at the Gi check point.
The p16 gene is frequently deleted, mutated, or methyl-
ated in many types of cancer, including squamous car-
cinoma of the head and neck.2-5 Moreover, transfection
studies reveal that p16 inhibits growth of squamous car-
cinoma cell lines by blocking cells in the G1-S transition
of the cell cycle.6 This growth inhibition operates
through inhibition of cdk4, which in turn inhibits phos-
phorylation of Rb to prevent entry into S phase. Inactiva-
tion or absence of p16 protein is therefore associated
with Rb phosphorylation, cell proliferation, and tumori-
genesis.
Cytogenetic and subsequent molecular evidence im-
plicates p16 defects in nasopharyngeal carcinogenesis.
Early work by Huang et a17 revealed chromosomal dele-
tions at 9p21-22, and a subsequent study confirmed the
presence of homozygous deletions in the vicinity of 9p21
in many NPCs.e More recently, mutation and hypermethy-
lation were reported to serve as alternate mechanisms of
p16 inactivation in NPCs.9 Down-regulation of p16 has
been demonstrated in two NPC cell lines by Northern blot
analysis. 10
Immunohistochemical studies of p16 expression have
not yet been reported in NPC, but in other head and neck
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carcinomas, a correlation exists between immunohisto-
chemical absence of p16 and deletion, mutation, or
methylation of the p16 gene.11 In fact, immunostains
were reported to be a simple and accurate method for
identifying p16 inactivation.11'12
The retinoblastoma protein, pRb, is a key cell cycle
regulator, the function of which is partially modulated by
p16. The Rb gene is mutated or otherwise inactivated in
a wide variety of tumor types, which in turn results in
absent or defective pRb. Several studies have identified
allele loss in the vicinity of the Rb gene in head and neck
cancers,13 but this loss was not necessarily associated
with absence of the Rb protein.14'15 One group reported
no Rb gene alterations in NPCs,16 but little is known
about pRb expression in NPCs.
Immunohistochemical assays for pRb and p16 are now
available for evaluating the presence or absence of pro-
tein product in tumor cells. Immunostains are advanta-
geous in their ability to demonstrate the absence of these
proteins regardless of the mechanism for that absence.
Specifically, homozygous deletion, hemizygous deletion
accompanied by mutation of the remaining allele, or hy-
permethylation usually result in no protein production.
Recent innovations now permit retrospective analysis of
p16 and pRb expression in routine formalin-fixed, paraf-
fin-embedded tissue sections. In the current study, we
evaluated 59 NPCs for p16 and pRb expression. Results
were interpreted in relationship to tumor histology, the
presence of EBV, and expression of p53.
Materials and Methods
Tissue Acquisition and Histopathological
Diagnosis
Paraffin-embedded NPC tissues from 59 patients were
collected retrospectively from files of medical centers in
San Antonio (n = 19), Houston (n = 8), Detroit (n = 5),
and Hong Kong (n = 27). These cases were previously
reported with respect to EBV association and p53 ex-
pression.17 Some cases of NPC were excluded from the




Rb immunostains were performed on paraffin-embedded
tissue sections using mouse anti-Rb monoclonal anti-
body 3C8 (QED, San Diego, CA) at a concentration of 2
,ug/ml for 2 hours after an antigen retrieval step, as pre-
viously described.18 p16 immunostains were performed
using two different anti-p16 antibodies (PharMingen, San
Diego, CA) in an overnight incubation. The polyclonal
antibody (rabbit anti-human p16) was used at a dilution of
1:400 at 40C as previously described.12 The monoclonal
p16 antibody (clone G175-405) was used at a concen-
tration of 2 ,tg/ml at room temperature after an antigen
retrieval step in hot citrate buffer. All three bound anti-
bodies were detected using the Vector Elite kit (Vector
Laboratories, Burlingame, CA) with diaminobenzidene
chromogen and hematoxylin counterstain.
The following external positive controls were used:
mesothelioma cell line H2373 for Rb and lung cancer cell
lines H417 and H2009, as well as a nude mouse xe-
nograft of H2009 cells, for p16. In addition, nonneoplastic
cells served as internal positive controls in every biopsy
sample. The following negative external controls were
used: cell lines H417 and H2009 for Rb and cell line
H2373 for p16. In addition, parallel sections of the tumors
were treated with nonspecific mouse IgG and rabbit se-
rum to control for nonspecific staining.
Rb and p16 stains were interpreted using previously
described scoring criteria.12'18 Only nuclear staining was
evaluated; cytoplasmic reactivity, if present, was disre-
garded. A tumor was considered positive (normal) for
pRb or p16 when there was distinct nuclear staining in all
areas of the neoplasm. A tumor was considered negative
(abnormal) when there was no definite nuclear staining
throughout the neoplasm in the context of preserved
nuclear reactivity in nonneoplastic cells of the same tis-
sue. If neither tumor nor normal cells showed definite
nuclear reactivity above cytoplasmic background, the
result was considered inconclusive.
Statistical Analysis
Statistical significance among categorical data was eval-




Fifty-nine cases of NPC were evaluated for pRb expres-
sion by immunohistochemical methods using the 3C8
antibody. Expression of pRb was localized to the tumor
cells of 54/54 (100%) evaluable cases of NPC. Five ad-
ditional cases were uninterpretable as a result of diffuse
nonspecific loss of immunoreactivity. Most tumors were
characterized by strong or moderate nuclear reactivity in
50 to 95% of neoplastic cells (Figure 1).
p 16 Expression
Immunohistochemical stains for p16 were performed us-
ing monoclonal and polyclonal antibodies. As an internal
control for p16 immunostains, normal reactive cells were
evaluated in the same tissue sections as the tumor (Fig-
ure 2); p16 was commonly identified in lymphocytes,
normal surface epithelium, and fibroblasts. Four cases of
NPC were excluded from the study because both mono-
clonal and polyclonal p16 immunostains were inconclu-
sive as a result of complete absence of staining in tumor
and reactive cells or because of excessively high back-
ground cytoplasmic staining that prevented accurate in-
terpretation of nuclear staining.
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Figure 1. A: Standard H&E stain of an NPC demonstrates undifferentiated Figure 2. Immunohistochemical stains for p16 tumor suppressor protein
malignant epithelial cells surrounded by lymphoid stroma. B: Immunohisto- reveal positive results in an NPC where tumor cells and reactive cells uni-
chemical stain for pRb protein reveals that pRb is expressed in the nucleus of formnly exhibit nuclear staining (A) and negative nuclear staining in the cells
the malignant epithelial cells. Magnification, x400. of another NPC accompanied by positive nuclear staining in scattered reac-
tive lymphoid cells and fibroblasts (B). Magnification, X400.
Of 59 tumors that were examined with the monoclonal
anti-p16 antibody (clone G175-405), 51 were interpret-
able for p16 expression. The remaining eight cases either
were diffusely nonreactive or had very strong cytoplas-
mic staining that precluded evaluation of the nuclei. Of
the 51 evaluable tumors, 38 (75%) diffusely lacked nu-
clear reactivity, although cytoplasmic reactivity of vari-
able intensity was observed in all cases. Nonneoplastic
cells exhibited nuclear staining in all of these cases. In
the 13 tumors that were positive for p16, 10 to 90% of
neoplastic cells showed weak to strong nuclear reactivity.
All samples were also tested for reactivity with the Phar-
Mingen polyclonal anti-p16 antibody, and a higher per-
centage of tumors displayed nuclear staining. However,
under the conditions used, the polyclonal anti-p16 anti-
body has been found to react with some cells known to
lack normal p16 protein (J. Geradts, unpublished data),
and thus these staining results were deemed less reli-
able. Nevertheless, the two antibodies gave comparable
staining results in many cases, and any discrepancies
were resolved in favor of the monoclonal antibody results.
Consensus interpretation revealed p16 expression in
21/59 NPCs (36%) and, conversely, absence of p16 in
38/59 NPCs (64%).
Correlation between p16 Expression and Other
Biological Variables
The same cohort of NPCs that was examined in the
current study had been previously examined for the pres-
ence of EBV by EBER1 in situ hybridization and for ex-
pression of p53 by immunostains using the D07 mono-
clonal antibody.17 EBV was detected in 83% of NPCs,
and p53 was accumulated in 85% of cases. When cor-
related with the results of the current study, no significant
association was found between expression of p16 and
the presence of EBV (P = 0.08). There was also no
association between expression of p16 and accumula-
tion of p53 (P = 0.9), although abnormalities of one or
both of these tumor suppressor proteins were identified in
nearly all tumors (56/59; 95%).
The NPCs were histologically classified as undifferen-
tiated (n = 46), poorly differentiated nonkeratinizing (n =
10), or keratinizing squamous cell carcinoma (n = 3).
Their geographic origin was the United States in 32 cases
and Hong Kong in 27 cases. There was no correlation
between p16 expression and geographic origin (P =
0.4). However, when p16 results were evaluated in the
context of tumor histology, p16 was more commonly ab-
sent in differentiated compared with undifferentiated
forms of NPC (P = 0.02; see Table 1).
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Table 1. Absence of p16 Expression in Histological Variants
of Nasopharyngeal Carcinoma (P = 0.02)
p16 negative
Undifferentiated 26/46 (57%)
Nonkeratinizing squamous 9/10 (90%)
Keratinizing squamous 3/3 (100%)
Total 38/59 (64%)
For the purposes of statistical analysis, the nonkeratinizing and
keratinizing subtypes were combined.
Discussion
The p16/MTS1 gene is one of the most frequently altered
genes in human cancers.19 This study reveals that NPCs
uniformly expressed pRb whereas 64% lacked the p16
tumor suppressor protein. The absence of p16 expres-
sion in a substantial proportion of NPCs points to the
importance of this gene in the genesis of these tumors.
The high rate of loss of p16 in NPC rivals that of the
most strongly associated cancers, including other head
and neck cancers (47 to 83%),3.11 lung cancer (30 to
70%),2o and breast cancer (49%) 21 In human tumors
where p16 is inactivated, the mechanism of inactivation is
usually deletion or methylation, which results in no protein
product, rather than gene mutation, which might truncate
or alter protein structure.22 The same mechanisms of
inactivation appear to operate in NPC where there are
reports of allele loss and methylation,89 but no mutation
of p16/MTS1 in any of 42 primary NPC biopsies.10 Our
study extends these previous findings by demonstrating
that the majority of NPCs actually lack detectable expres-
sion of p16 protein.
When comparing p16-expressing NPCs to those lack-
ing p16, no link was identified between p16 and either
EBV infection or p53 overexpression. However, these
results should be interpreted with caution because of the
relatively small number of cases that were examined. If
confirmed in larger studies, these results imply that inac-
tivation of p16 is independent of other molecular events
that have been implicated in tumorigenesis. Although
there was no association between expression of p16 and
accumulation of p53, abnormalities of one or both of
these tumor suppressor proteins were identified in nearly
all tumors (56/59; 95%). In fact, only 3 of 59 cases had
normal levels of both p16 and p53 tumor suppressor
proteins. This suggests a nearly absolute requirement for
loss of cell cycle control in NPCs.
When p16 results were evaluated in the context of
tumor histology, p16 expression was more frequently lost
in the differentiated NPCs compared with undifferentiated
NPCs. But even the undifferentiated tumors failed to ex-
press p16 in the majority of cases (57%), revealing that
cofactors other than p16 contribute to tumor morphology.
Additional studies are warranted to examine the effects of
p16 on tumor behavior and response to therapy. Not only
might p16 be a prognostic factor, but it might also be a
potential target for gene replacement therapy.
In the current study, pRb was detected by immunohis-
tochemistry in all evaluable NPCs. This result implies that
the Rb gene is unlikely to be deleted or mutated; how-
ever, immunostains are blind to the phosphorylation sta-
tus of the pRb, so the identification of pRb in tissue
sections does not exclude functional inactivation of this
protein. 8
Previous studies of other types of cancer have shown
that p16 and pRb are inactivated in a wide spectrum of
human neoplasms, but rarely are both proteins inacti-
vated in the same tumor sample.61223 For example,
small-cell lung cancers are usually pRb negative and p16
positive,24 whereas the opposite is true for mesothelio-
25 26mas and pancreatic adenocarcinomas. It may be
expected that inactivation of p16 and pRb are mutually
exclusive as p16 operates in the same biochemical path-
way as pRb. Specifically, p16 inhibits cdk4-mediated
phosphorylation of pRb to block progression of the G1-S
phase of the cell cycle. In contrast, p53 operates through
separate pathways to halt the cell cycle or trigger apo-
ptosis in the event of DNA damage. Therefore, it is logical
that defects of both p16 and p53 might co-exist in the
same tumor, and indeed this appears to be the case in
NPCs.
In summary, this study demonstrates that NPCs are
frequently characterized by absence of p16 but preser-
vation of pRb expression. The findings imply that p16
inactivation contributes to the multistep process of naso-
pharyngeal carcinogenesis and, in fact, is one of the
most common molecular alterations in this tumor type.
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